Overview
Quick answer
Oestradiol (E2) is the main oestrogen circulating in a cycling woman. An Australian pathology report prints it in pmol/L, usually beside follicle-stimulating hormone (FSH), luteinising hormone (LH), progesterone, and sex hormone-binding globulin (SHBG). Those five lines are a panel, not five separate verdicts.
A single oestradiol or FSH result does not diagnose perimenopause at the usual age. The Australasian Menopause Society tells clinicians not to measure FSH, oestradiol, LH, anti-Mullerian hormone (AMH), or testosterone in a woman with typical symptoms over 45, because the hormones swing day to day and the result will not change management. That story lives on the perimenopause blood tests guide. This page is the marker walkthrough: units, cycle-phase fields, and when the same assays still earn their keep.
Read the number against the cycle day or menopause status printed on the request, and against the interval on that lab report. RCPA publishes example adult intervals by phase. Your lab will not always match them. A US result in pg/mL is a different unit (pg/mL × 3.671 ≈ pmol/L) and cannot be compared raw.
Overview
Key takeaways
Australian labs report oestradiol in pmol/L, FSH and LH in IU/L or U/L, progesterone and SHBG in nmol/L. Those are the units on a Healius, Australian Clinical Labs, or Sullivan Nicolaides printout.
Oestradiol is not a free-floating "hormone level." Most of it is bound to SHBG and albumin. The free fraction is the part that can enter cells and bind estrogen receptors ERα and ERβ.
RCPA example intervals (last reviewed 2 January 2024) put early-follicular oestradiol at 100 to 200 pmol/L, preovulatory at 500 to 1700, luteal at 500 to 900, and postmenopausal at 70 to 200. Treat those as examples. Method and lab change the printed range.
Collection timing is the clinical question, not a calendar superstition. Early-cycle FSH and oestradiol describe the follicular baseline. Progesterone is a mid-luteal test, about seven days before the next period, which is only "day 21" on a 28-day cycle.
Over 45 with typical symptoms, AMS and the 2023 Practitioner's Toolkit say hormone bloods are not a menopause test. Under 45, after hysterectomy, or when another illness is plausible, FSH (and often oestradiol) still matters. Premature ovarian insufficiency needs elevated FSH on two occasions, 4 to 6 weeks apart.
AMH is not a menopause test. RANZCOG does not recommend it to predict or diagnose menopause. On Hemexa it is an add-on, not a silent inclusion.
Do not interpret these assays on the combined pill or menopausal hormone therapy. Symptoms, not biochemistry, guide that therapy.
Medicare item 66695 covers one hormone or binding-protein assay (schedule fee $30.50) when clinically indicated, including oestradiol, FSH, LH, progesterone, and SHBG. Extra assays on the same request use the related P2 items.
Basics
What oestradiol does
Oestradiol is a steroid hormone made mainly by granulosa cells in a developing ovarian follicle, from androgen precursors, under FSH drive. After ovulation the corpus luteum keeps producing it, alongside progesterone. After menopause, circulating oestradiol falls and most of what remains is made in fat, bone, and other peripheral tissue by aromatising adrenal androgens.
Two receptors, many tissues
Free oestradiol enters cells and binds two nuclear receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). The receptors dimerise, sit on estrogen response elements, and change transcription. That is the settled mechanism behind effects on endometrium, bone, breast, liver, and brain. It is also why a blood level is a circulating concentration, not a direct read of receptor activity in any one tissue.
Most of the number is bound
SHBG, made in the liver, binds dihydrotestosterone, testosterone, and oestradiol. Albumin binds a further share more loosely. Only a small unbound fraction is treated as immediately bioavailable. Insulin resistance and androgens lower SHBG, which raises the free fraction of both testosterone and oestradiol. Oral oestrogen raises SHBG. That is why the same total oestradiol can mean different things beside a different SHBG.
Feedback, then a surge
Rising follicular oestradiol first suppresses FSH (negative feedback), then, at a high enough level for long enough, flips to positive feedback and helps trigger the LH surge that precedes ovulation. That switch is why a mid-cycle oestradiol in the high hundreds or above 1000 pmol/L can be physiology, not pathology, and why the same number after menopause would be read completely differently.
That production path is why a lone oestradiol number is almost never read alone. FSH tells you what the pituitary is asking the ovary to do. LH marks the mid-cycle surge that usually precedes ovulation. Progesterone tells you whether a corpus luteum formed. SHBG tells you how much of the measured oestradiol is actually free to act.
The panel
What the female hormone panel measures
A useful Australian female hormone request is a set, not an oestradiol line on its own. These are the fields that usually travel together, and the job each one actually has.
Oestradiol (E2)
Printed in pmol/L. The main circulating oestrogen in a cycling woman. RCPA lists uses that are clinical, not wellness screening: suspected hypothalamic or pituitary disease, monitoring ovulation induction, precocious puberty, and monitoring oestrogen therapy only when the drug being given is oestradiol. Immunoassay is standard; LC-MS/MS is more specific at low concentrations.
FSH
Printed in IU/L or U/L. The pituitary signal that recruits follicles. RCPA: method-dependent and related to the menstrual cycle. Example adult female interval 1.0 to 8.0 U/L, postmenopausal above 18.0 U/L. Raised when the ovary is not feeding back (primary ovarian insufficiency, post-menopause). Low when the problem is pituitary or hypothalamic.
LH
Printed in IU/L or U/L. The mid-cycle surge usually precedes ovulation by about a day. A random LH without a cycle day is easy to over-read. With FSH it helps separate primary from secondary hypogonadism. It is not a home ovulation-kit substitute, and a home LH surge is not proof that ovulation occurred.
Progesterone
Printed in nmol/L. Rises after ovulation from the corpus luteum. RCPA example intervals: follicular 2.0 to 4.5 nmol/L, luteal 7.0 to 70.0 nmol/L. Failure to rise in the latter part of the cycle points to an anovulatory cycle or a luteal-phase problem. Timing is the whole test.
SHBG
Printed in nmol/L. The liver protein that binds testosterone and oestradiol. Low SHBG is common in insulin resistance and PCOS and raises the free androgen (and oestradiol) fraction. Oral oestrogen raises it. Read testosterone and oestradiol with this row, not against it.
AMH (add-on, not a menopause test)
Printed in pmol/L in Australia. A marker of ovarian reserve used in fertility work. RANZCOG does not recommend it to predict or diagnose menopause. AMS lists it in the do-not-measure set over 45. Hemexa does not include it on the annual baseline.
Reading your results
How to read an Australian hormone printout
An Australian hormone printout is easy to misread if you treat it like a cholesterol report: one number, one flag, one story. These fields change the meaning of every line.
The analyte name
Look for "Oestradiol" or "Estradiol (E2)", "FSH", "LH", "Progesterone", and "SHBG". Some reports still use the US spelling estradiol. It is the same molecule. Oestrone and oestriol are different oestrogens and are not this test.
The unit
Oestradiol in pmol/L. A US clinic or an imported PDF often uses pg/mL. Convert with the molar factor from oestradiol's molecular weight (272.38 g/mol): pg/mL × 3.671 ≈ pmol/L, or pmol/L ÷ 3.671 ≈ pg/mL. Example: 50 pg/mL is about 184 pmol/L. Do not compare a pg/mL number to an Australian pmol/L interval.
The cycle-phase or menopause label
Many Australian reports print a different reference interval for follicular, mid-cycle, luteal, and postmenopausal. The flag on the right is only as good as the phase the lab assigned. If the request did not name a cycle day, the lab may have used a broad female interval, or the wrong phase, and a "high" or "low" flag can be an artefact of that choice.
The reference interval on that report
RCPA example early-follicular oestradiol is 100 to 200 pmol/L. Some Australian labs print a wider follicular band. Both can be internally consistent for their assay. Use the interval printed beside your result, then ask whether the phase label is right, rather than shopping for a friendlier range online.
| Phase | RCPA example oestradiol | How to read it |
|---|---|---|
| Early follicular | 100 to 200 pmol/L | RCPA example. Method-dependent. |
| Preovulatory | 500 to 1700 pmol/L | The mid-cycle peak can be physiology. |
| Luteal | 500 to 900 pmol/L | Read with progesterone, not alone. |
| Postmenopausal | 70 to 200 pmol/L | A cycling-phase interval does not apply here. |
If two reports disagree, check units and phase first. A luteal oestradiol of 600 pmol/L can sit inside an RCPA luteal example (500 to 900) and look "high" against an early-follicular band. That is a labelling problem, not a new diagnosis.
Collection
When to collect, and why day 21 is often wrong
The same assays answer different questions on different days. Collecting "whenever" is how a useful panel becomes a confusing PDF.
Early follicular (often day 2 to 3) for FSH and oestradiol
When the question is ovarian reserve context, amenorrhoea, or a suspected premature menopause, clinicians time FSH (and usually oestradiol) to the start of a bleed if the woman is still cycling. That is the low, relatively stable part of the oestradiol curve, before the mid-cycle rise. RCPA does not print a single mandatory calendar day; the clinical question sets the timing.
Mid-luteal for progesterone, not automatically day 21
Progesterone is used to ask whether ovulation happened. The useful window is the mid-luteal phase: about seven days before the next period. On a 28-day cycle that lands near day 21. On a 35-day cycle, day 21 is still follicular and a "low" progesterone is expected. Date it from the next period, or from a documented ovulation, not from a generic day-21 stamp.
Do not chase a number on the pill or MHT
AMS is blunt: it is especially unhelpful to do hormone blood tests while a woman is on menopausal hormone therapy or the combined oral contraceptive. Those medicines change the biochemistry you are trying to read. Symptoms, not the blood level, guide that therapy.
If the same draw also includes fasting glucose, insulin, or a lipid profile, follow the fasting instruction for those markers. The hormone assays themselves do not require an overnight fast on the RCPA Manual pages for oestradiol, FSH, or progesterone.
Limits
What a single result cannot diagnose
This is the section most Australian oestradiol pages skip, and it is the one that stops a printout from being over-read.
Perimenopause over 45
AMS diagnoses perimenopause clinically: new vasomotor or other symptoms plus a change in bleeding. Average age of menopause in Australian women is 51 (usual range 45 to 55). A single FSH or oestradiol pair cannot stage you. Oestradiol can briefly run high in the transition, which is why breast tenderness or heavy bleeding can appear even as the ovaries are winding down. The useful bloods in that decade are thyroid, iron, lipids, and glucose. See the perimenopause guide.
A fertility verdict from one draw
One follicular FSH does not measure egg count. AMH and ultrasound are the reserve tools, used in a fertility clinic for a fertility question. RCPA notes that AMH is a more reliable marker of ovarian reserve than FSH, and still does not make AMH a menopause test.
"Hormone imbalance" as a diagnosis
Laboratories report concentrations. They do not name a syndrome. PCOS has its own diagnostic rule (two of three after exclusion). Premature ovarian insufficiency has a repeated-FSH rule. Perimenopause is clinical. A flagged oestradiol line is a prompt to match the number to the cycle day and the question, not a standalone label.
Under 45, after hysterectomy when cycles cannot be read, or when another illness is on the table, the same assays become useful again. Premature ovarian insufficiency (before 40) needs elevated FSH on two occasions, 4 to 6 weeks apart. The 2023 Toolkit also asks for a low oestradiol on those paired draws. AMS does not print a single national FSH cut-off in IU/L on the diagnosing-menopause sheet, so this page does not invent one.
For the clinical diagnosis, and the bloods that still matter in that decade, see the perimenopause blood tests guide. For the androgen side of a PCOS workup, see the PCOS guide.
Beyond the reference range
Reference range vs a preventative target
A reference interval is a population statistic for that assay and that cycle phase. It answers "is this an unusual result for the group the lab used to build the range?" It does not answer "is this the most useful level for this person over time?"
Phase-specific intervals are the first filter
Unlike ferritin or HbA1c, oestradiol does not have one Australian clinical cut-off that everyone argues about. The first job is to put the result in the right physiological bin: follicular, mid-cycle, luteal, or postmenopausal. A result inside the printed band can still be the wrong phase. A result outside the band can still be a normal mid-cycle peak.
Hemexa does not publish a single optimal oestradiol
Hemexa applies its own cycle-phase preventative bands in the member app. Those rows in the live database conflict across phases, and several cite a single-state lab brand, so this page does not quote a Hemexa "optimal" oestradiol, FSH, LH, or progesterone. Use the interval on your own report. Treat any dashboard band as company policy layered on the reporting lab, not as AMS or RCPA consensus.
Trend still has a job
On a preventative female baseline the value is a dated snapshot: which phase, which assay, which lab. Year-on-year comparison only works if those three stay comparable. Switching labs, switching immunoassay to LC-MS/MS, or comparing a luteal draw to last year's day-3 draw will manufacture a change that is not biology.
Cycle-dependent hormone intervals are a special case of the same problem. The wider argument is on the reference range vs optimal range guide.
Who should test
Who should consider a hormone panel?
Order these tests for a question they can answer. That is a shorter list than "I want my hormones checked."
Questions the panel can help with
- Amenorrhoea or markedly irregular cycles under 45, including a suspected premature ovarian insufficiency workup (paired FSH, 4 to 6 weeks apart).
- A fertility or ovulation question, with progesterone timed to the mid-luteal phase.
- A PCOS workup, where androgens and SHBG do more work than oestradiol, and a 75 g oral glucose tolerance test is the glycaemic test the 2023 guideline asks for. See the PCOS guide.
- Suspected hypothalamic or pituitary disease, which is an RCPA-listed application for oestradiol and FSH.
- Men on or considering testosterone therapy, where a clinician may add oestradiol because testosterone aromatises to E2. That is not on Hemexa's male baseline.
Questions it usually cannot settle
- Typical perimenopause over 45. Diagnosis is clinical.
- Whether to start, stop, or dose menopausal hormone therapy. Symptoms guide that.
- A saliva kit or an online "optimal oestrogen" chart copied from a US pg/mL range.
A preventative female baseline that includes these markers is a dated record, not a diagnosis. It is useful the year you want a comparable repeat, and misleading the year you use it to name a transition AMS says not to blood-test.
The other direction
When oestradiol runs high
High oestradiol is not automatically a problem, and it is not automatically "oestrogen dominance." The phase and the medicines come first.
The mid-cycle peak is supposed to be high
RCPA's preovulatory example runs to 1700 pmol/L. A result in the high hundreds or low thousands near ovulation is often the LH-surge physiology described above, especially if LH is also up and the cycle day fits.
Exogenous oestrogen makes the number unreadable
RCPA notes that monitoring oestrogen therapy is only possible if the drug being given is oestradiol. Combined oral contraceptives and many MHT preparations will move, suppress, or simply confuse the immunoassay. Do not titrate those medicines off a single private printout.
Men: aromatisation, not an ovarian cycle
In men, oestradiol is made by aromatase (CYP19A1) from testosterone, including in adipose tissue. A high male result is a different conversation (adiposity, liver, exogenous testosterone, rarely a tumour) and is not interpreted against a female cycle-phase interval. Hemexa does not include oestradiol on the male annual baseline.
How to order
How Australians get these tests
| Approach | Best for | Typical cost | Includes the panel? |
|---|---|---|---|
| GP request, clinically indicated | Amenorrhoea, infertility, suspected POI, pituitary disease | Often bulk-billed or low gap. MBS 66695 is $30.50 for one assay. | The assays the GP names. Extra hormones on the same request use related P2 items. |
| GP-ordered private hormone panel | A timed follicular or mid-luteal set without a rebate indication | Varies by lab and how many analytes are added. | Usually oestradiol, FSH, LH, progesterone; SHBG if androgens are included. |
| Membership baseline (e.g. Hemexa) | An annual dated snapshot with the rest of the female panel | ~$1,199/year (full membership) | Oestradiol, FSH, LH, and progesterone among 76–80 signature markers. SHBG is on every member's baseline. AMH and prolactin are add-ons. |
Pathology in Australia requires an authorised request from a registered medical practitioner. Write the cycle day, or "postmenopausal," or "on COCP / MHT" on the request. Collection is a serum tube. Healius Pathology is Hemexa's collection partner, with regional brands that differ by state.
FAQ
Frequently asked questions
- What is a normal oestradiol level in Australia?
- There is no single normal. RCPA example intervals (last reviewed 2 January 2024) are 100 to 200 pmol/L early follicular, 500 to 1700 preovulatory, 500 to 900 luteal, and 70 to 200 postmenopausal. Your lab prints its own interval for its assay. Use that interval, and the phase label, rather than a number copied from a US site in pg/mL.
- How do I convert a US oestradiol result in pg/mL?
- Multiply pg/mL by 3.671 to get pmol/L, or divide pmol/L by 3.671 to get pg/mL. The factor comes from oestradiol's molecular weight of 272.38 g/mol. Example: 50 pg/mL is about 184 pmol/L. Then read the converted number against an Australian interval for the same cycle phase, not against the US lab's pg/mL range.
- Can a blood test diagnose perimenopause?
- Not at the usual age. AMS and Healthdirect treat perimenopause as a clinical diagnosis. A single FSH or oestradiol result fluctuates day to day and can briefly run high. Hormone testing is for women under 45, after hysterectomy, or when another illness is plausible. See the perimenopause blood tests guide.
- Do I need to test on day 21?
- Only if day 21 is actually mid-luteal for your cycle, which is true for a 28-day cycle and wrong for a longer or shorter one. Progesterone should be timed to about seven days before the next period, or about seven days after documented ovulation. FSH and oestradiol, when they are being used as a follicular baseline, are usually collected near the start of a bleed.
- Do I need to fast?
- Not for oestradiol, FSH, LH, or progesterone on the RCPA Manual pages. Fast if the same collection includes glucose, insulin, or a lipid profile, because those markers do care about the last meal.
- Can I test on the pill or on menopausal hormone therapy?
- You can draw the blood. You usually should not interpret it as your underlying ovarian function. AMS says it is especially unhelpful to do these tests on MHT or the combined oral contraceptive, because symptoms, not biochemistry, guide that therapy.
- Does Medicare cover an oestradiol test?
- When clinically indicated, yes. MBS item 66695 covers quantitation of one listed hormone or binding protein, including oestradiol, FSH, LH, progesterone, and SHBG, with a schedule fee of $30.50. Extra assays on the same request use the related P2 items. Broad screening without a clinical indication is typically private.
- Is AMH a better menopause test than oestradiol?
- Neither is a menopause test at the usual age. RANZCOG does not recommend AMH to predict or diagnose menopause. AMS tells clinicians not to measure AMH, FSH, or oestradiol over 45 with typical symptoms. AMH is a fertility-reserve marker, and on Hemexa it is an add-on.
- Should men have an oestradiol test?
- Sometimes, when a clinician is investigating gynecomastia, hypogonadism, or monitoring testosterone therapy, because testosterone is aromatised to oestradiol. Male results are not read against a female cycle-phase interval. Hemexa's oestradiol, FSH, LH, and progesterone markers are female-only on the annual baseline.
- Are saliva hormone tests useful?
- Not as a substitute for a serum panel in this setting. The Australian sources this guide uses (AMS, RANZCOG, RCPA) discuss blood. This page does not treat a consumer saliva kit as equivalent to a NATA-accredited serum immunoassay or LC-MS/MS result.
How Hemexa fits
How Hemexa can help
The female hormone set is the reason a woman's Hemexa baseline is larger than a man's. The job of those extra markers is a dated, comparable snapshot, not a menopause diagnosis.
Four female-only markers on the annual baseline
Oestradiol, FSH, LH, and progesterone are the 4 female-only baseline markers. That is why a woman's panel runs 80 markers and a man's runs 76. SHBG is annual for every member. AMH and prolactin are add-ons, not silent inclusions.
Dashboard bands are Hemexa policy
The member app applies cycle-phase preventative bands to these results. Live policy rows conflict across phases and several cite a single-state lab brand, so this page does not quote a Hemexa optimal oestradiol or FSH. Read the interval on your report first. Treat the dashboard as company policy layered on the reporting lab.
Collection through Healius Pathology
Healius Pathology is Hemexa's collection partner, with regional brands that differ by state. Write the cycle day on the request. Results from other Australian labs can be imported after the first baseline. Hemexa does not diagnose perimenopause, PCOS, or fertility, and does not prescribe menopausal hormone therapy.
Sources
References
Royal College of Pathologists of Australasia. Oestradiol (RCPA Manual, last reviewed 2 January 2024). View source ↗
Royal College of Pathologists of Australasia. Follicle stimulating hormone (RCPA Manual, last reviewed 2 January 2024). View source ↗
Royal College of Pathologists of Australasia. Progesterone (RCPA Manual). View source ↗
Australasian Menopause Society. Diagnosing menopause (information sheet). View source ↗
Australasian Menopause Society. What is menopause? (information sheet). View source ↗